Contribute Try STAT+ Today

You can add Maine to the growing list of states that have passed a law seeking more transparency about prescription drug pricing.

However, unlike a few states that quickly required drug makers to provide cost and pricing information about their medicines – California, Vermont, Nevada, and Oregon — Maine is taking a two-step approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • This line struck me – “passing legislation to lower drug costs should be a “top priority” for President Trump, who is expected to deliver a speech about the issue.”
    I thought the President’s objection to the last administration was ‘all talk and no action’ – the tradition continues, it would seem. (And wasn’t said speech due last week?)

Comments are closed.